Apogossypol Derivatives As Pan-active Inhibitors of Antiapoptotic B-cell Lymphoma/leukemia-2 (Bcl-2) Family Proteins

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2009 Jun 27

PMID 19555126

Citations 27

Authors

Jun Wei

Shinichi Kitada

Michele F Rega

John L Stebbins

Dayong Zhai

Jason Cellitti

Hongbin Yuan

Aras Emdadi

Russell Dahl

Ziming Zhang

Li Yang

John C Reed

Maurizio Pellecchia

Affiliations

Soon will be listed here.

Abstract

Guided by nuclear magnetic resonance (NMR) binding assays and computational docking studies, a series of 5,5' substituted apogossypol derivatives was synthesized that resulted in potent pan-active inhibitors of antiapoptotic Bcl-2 family proteins. Compound 8r inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 0.76, 0.32, 0.28, and 0.73 microM, respectively. The compound also potently inhibits cell growth of human lung cancer and BP3 human B-cell lymphoma cell lines with EC(50) values of 0.33 and 0.66 microM, respectively. Compound 8r shows little cytotoxicity against bax(-/-)bak(-/-) cells, indicating that it kills cancers cells via the intended mechanism. The compound also displays in vivo efficacy in transgenic mice in which Bcl-2 is overexpressed in splenic B-cells. Together with its improved chemical, plasma, and microsomal stability relative to compound 2 (apogossypol), compound 8r represents a promising drug lead for the development of novel apoptosis-based therapies for cancer.

Citing Articles

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma.

Ailawadhi S, Parrondo R, Dutta N, Han B, Ciccio G, Cherukuri Y Cancers (Basel). 2023; 15(2).

PMID: 36672426 PMC: 9857228. DOI: 10.3390/cancers15020477.

Practical Strategy to 1,1'-Dideoxygossypol Derivatives from Gossypol and Its Antitumor Activities.

Wang W, Lu Y, Ge J, Liu N ACS Omega. 2022; 7(26):22938-22943.

PMID: 35811914 PMC: 9260933. DOI: 10.1021/acsomega.2c02955.

Comprehensive analysis of autophagy-related genes and patterns of immune cell infiltration in valvular atrial fibrillation.

Liu A, Jia K, Liang H, Jin Q BMC Cardiovasc Disord. 2021; 21(1):132.

PMID: 33706714 PMC: 7948357. DOI: 10.1186/s12872-021-01939-1.

Apogossypol-mediated reorganisation of the endoplasmic reticulum antagonises mitochondrial fission and apoptosis.

Yedida G, Milani M, Cohen G, Varadarajan S Cell Death Dis. 2019; 10(7):521.

PMID: 31285422 PMC: 6614446. DOI: 10.1038/s41419-019-1759-y.

Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening.

Mady A, Liao C, Bajwa N, Kump K, Abulwerdi F, Lev K Sci Rep. 2018; 8(1):10210.

PMID: 29976942 PMC: 6033896. DOI: 10.1038/s41598-018-27899-9.

References

Reed J . Bcl-2 family proteins. Oncogene. 1999; 17(25):3225-36. DOI: 10.1038/sj.onc.1202591. View

Voortman J, Checinska A, Giaccone G, Rodriguez J, Kruyt F . Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther. 2007; 6(3):1046-53. DOI: 10.1158/1535-7163.MCT-06-0577. View

Ferreira C, Span S, Peters G, Kruyt F, Giaccone G . Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 2001; 60(24):7133-41. View

Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T . Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001; 3(2):173-82. DOI: 10.1038/35055085. View

Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer M . Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009; 16(7):1030-9. DOI: 10.1038/cdd.2009.48. View

Wang J, Liu D, Zhang Z, Shan S, Han X, Srinivasula S . Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000; 97(13):7124-9. PMC: 16510. DOI: 10.1073/pnas.97.13.7124. View

Tang G, Ding K, Nikolovska-Coleska Z, Yang C, Qiu S, Shangary S . Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. J Med Chem. 2007; 50(14):3163-6. PMC: 2527594. DOI: 10.1021/jm070383c. View

Ramjaun A, Tomlinson S, Eddaoudi A, Downward J . Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis. Oncogene. 2006; 26(7):970-81. DOI: 10.1038/sj.onc.1209852. View

Wesarg E, Hoffarth S, Wiewrodt R, Kroll M, Biesterfeld S, Huber C . Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer. 2007; 121(11):2387-94. DOI: 10.1002/ijc.22977. View

10.

Reed J . Apoptosis-based therapies. Nat Rev Drug Discov. 2002; 1(2):111-21. DOI: 10.1038/nrd726. View

11.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

12.

Adams J, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381):1322-6. DOI: 10.1126/science.281.5381.1322. View

13.

Wei M, Zong W, Cheng E, LINDSTEN T, Panoutsakopoulou V, Ross A . Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292(5517):727-30. PMC: 3049805. DOI: 10.1126/science.1059108. View

14.

Wei J, Kitada S, Rega M, Emdadi A, Yuan H, Cellitti J . Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2009; 8(4):904-13. PMC: 2750823. DOI: 10.1158/1535-7163.MCT-08-1050. View

15.

Johnstone R, Ruefli A, Lowe S . Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108(2):153-64. DOI: 10.1016/s0092-8674(02)00625-6. View

16.

Reed J . Dysregulation of apoptosis in cancer. J Clin Oncol. 1999; 17(9):2941-53. DOI: 10.1200/JCO.1999.17.9.2941. View

17.

Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q . Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther. 2008; 7(7):2192-202. PMC: 2515935. DOI: 10.1158/1535-7163.MCT-08-0333. View

18.

Jones G, Willett P, Glen R, Leach A, Taylor R . Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997; 267(3):727-48. DOI: 10.1006/jmbi.1996.0897. View

19.

Sattler M, Liang H, Nettesheim D, Meadows R, Harlan J, Eberstadt M . Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science. 1997; 275(5302):983-6. DOI: 10.1126/science.275.5302.983. View

20.

Katsumata M, Siegel R, Louie D, Miyashita T, Tsujimoto Y, Nowell P . Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A. 1992; 89(23):11376-80. PMC: 50553. DOI: 10.1073/pnas.89.23.11376. View